
Corrado Ficorella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7641204/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stageAsmall-cell lung cancer (CeLEBrATE study): background, design and rationale. Future Oncology, 2022, 18, 771-779.	2.4	3
2	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	2.8	81
3	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. International Journal of Medical Sciences, 2021, 18, 2245-2250.	2.5	5
4	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17
5	Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	2.8	19
6	Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	2.8	24
7	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Lifeâ€, Case-Control Study. Clinical Colorectal Cancer, 2021, , .	2.3	8
8	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Scientific Reports, 2021, 11, 13770.	3.3	8
9	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	3.2	6
10	Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. Supportive Care in Cancer, 2020, 28, 1051-1058.	2.2	0
11	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel antiâ€HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	5.1	4
12	The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings. Palliative and Supportive Care, 2020, 18, 33-38.	1.0	4
13	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer, 2020, 150, 123-131.	2.0	13
14	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. Cancers, 2020, 12, 2457.	3.7	3
15	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers, 2020, 12, 2598.	3.7	11
16	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE―Study. Cancers, 2020, 12, 1259.	3.7	19
17	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. International Journal of Colorectal Disease, 2020, 35, 1513-1527.	2.2	7
18	Rare bone toxicity associated with vismodegib. JAAD Case Reports, 2020, 6, 482-485.	0.8	1

CORRADO FICORELLA

#	Article	IF	CITATIONS
19	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂ≥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	2.6	50
20	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunotherapy, 2020, 12, 151-159.	2.0	16
21	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. Journal of Addictive Diseases, 2020, 38, 229-234.	1.3	4
22	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	2.8	85
23	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. Journal of Gastrointestinal Cancer, 2020, 51, 1094-1101.	1.3	2
24	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Realâ€world evidence. Journal of Cellular Physiology, 2020, 235, 7900-7910.	4.1	19
25	Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Scientific Reports, 2020, 10, 1456.	3.3	64
26	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. Journal of Thoracic Disease, 2020, 12, 6107-6111.	1.4	1
27	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. Palliative and Supportive Care, 2019, 17, 82-86.	1.0	4
28	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2365-2373.	2.5	9
29	Cancer Care After Natural Disaster: Different Countries, Similar Problems. Journal of Global Oncology, 2019, 5, 1-2.	0.5	7
30	<p>Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p> . OncoTargets and Therapy, 2019, Volume 12, 2159-2170.	2.0	8
31	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. Journal of Oncology Pharmacy Practice, 2019, 25, 1439-1444.	0.9	9
32	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
33	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. Journal of Cancer, 2019, 10, 5926-5934.	2.5	24
34	Family history of cancer and DNA damage response genes: Two sides of the same coin?. Thoracic Cancer, 2019, 10, 401-401.	1.9	1
35	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in nonâ€small cell lung cancer patients: A "hypothesisâ€generator―preliminary report. Thoracic Cancer, 2019, 10, 347-351.	1.9	54
36	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. Journal of Cellular Physiology, 2019, 234, 7708-7717.	4.1	21

CORRADO FICORELLA

#	Article	IF	CITATIONS
37	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study Journal of Clinical Oncology, 2019, 37, e16013-e16013.	1.6	1
38	Survivorship in young women after early breast cancer: a cross-sectional study of emotional traits along 3-years perspective. Rivista Di Psichiatria, 2019, 54, 160-167.	0.6	14
39	Multicentric retrospective analysis of platinumâ€pemetrexed regimens as firstâ€line therapy in nonâ€squamous nonâ€small cell lung cancer patients: A "snapshot―from clinical practice. Thoracic Cancer, 2018, 9, 241-252.	1.9	6
40	KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. Human Pathology, 2018, 74, 178-182.	2.0	5
41	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the <i>FAMI-L1</i> study. Immunotherapy, 2018, 10, 643-655.	2.0	15
42	Where are we with treatment options after first line in small cell lung cancer?°™report of two opposite cases treated with CAPTEM regimen and possible perspectives. Journal of Thoracic Disease, 2018, 10, E520-E525.	1.4	0
43	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. Journal of Clinical Neuromuscular Disease, 2018, 20, 99-100.	0.7	2
44	Singleâ€institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in nonâ€small cell lung cancer patients treated with firstâ€line chemotherapy. Thoracic Cancer, 2018, 9, 1623-1630.	1.9	38
45	"Palliative―or "Supportive― Is It Just a Matter of Word?. Journal of Palliative Medicine, 2018, 21, 1546-1546.	1.1	0
46	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. Immunotherapy, 2018, 10, 1229-1239.	2.0	38
47	Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. Oncology Reports, 2018, 40, 803-812.	2.6	3
48	Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers Journal of Clinical Oncology, 2018, 36, 673-673.	1.6	0
49	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen Journal of Clinical Oncology, 2018, 36, 178-178.	1.6	0
50	Integration between Oncology and Palliative Care: A Plan for the Next Decade?. Tumori, 2017, 103, e23-e23.	1.1	0
51	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 2017, 8, 56921-56931.	1.8	53
52	Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. Oncotarget, 2017, 8, 72031-72043.	1.8	6
53	Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. Indian Journal of Palliative Care, 2017, 23, 350.	1.0	10
54	Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer. Oncology Reports, 2016, 36, 125-130.	2.6	9

CORRADO FICORELLA

#	Article	IF	CITATIONS
55	Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. Bone, 2016, 87, 169-175.	2.9	16
56	New schedule of bevacizumab/paclitaxel as firstâ€line therapy for metastatic HER2â€negative breast cancer in a realâ€life setting. Cancer Medicine, 2016, 5, 2232-2239.	2.8	7
57	Comment on â€~What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion'. Drugs, 2016, 76, 1059-1061.	10.9	1
58	The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. Critical Reviews in Oncology/Hematology, 2015, 93, 190-202.	4.4	24
59	Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. BioMed Research International, 2014, 2014, 1-11.	1.9	10
60	Rapid Resolution of Refractory Chemotherapy-Induced Oral Mucositis With Platelet Gel-Released Supernatant in a Pediatric Cancer Patient: A Case Report. Journal of Pain and Symptom Management, 2014, 48, e2-e4.	1.2	7
61	Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. International Journal of Oncology, 2014, 44, 1820-1830.	3.3	10
62	Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. International Journal of Oncology, 2014, 44, 2121-2131.	3.3	64
63	c.35 G > A KRAS-mutant genotype and clinical outcome of patients with metastatic colorectal cancer Journal of Clinical Oncology, 2014, 32, 512-512.	1.6	0
64	Integrating Oncology and Palliative Home Care in Italy: The Experience of the "L'Aquila per la Vita― Home Care Unit. Tumori, 2013, 99, 225-228.	1.1	8
65	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. Clinical Colorectal Cancer, 2012, 11, 229-237.	2.3	18
66	Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to <i>KRAS </i> genotype and disease extension Journal of Clinical Oncology, 2012, 30, e14010-e14010.	1.6	0
67	P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer. Oncology Reports, 2003, 10, 169-73.	2.6	10